Secondary Cytoreductive Surgery in Platinum-Sensitive Recurrent Ovarian Cancer: A Meta-Analysis

被引:52
作者
Baek, Min-Hyun [1 ]
Park, Eun Young [2 ,3 ]
Ha, Hyeong In [4 ]
Park, Sang-Yoon [5 ,6 ]
Lim, Myong Cheol [5 ,6 ,7 ,8 ,9 ]
Fotopoulou, Christina [10 ]
Bristow, Robert E. [11 ]
机构
[1] Hallym Univ, Dept Obstet & Gynecol, Sacred Heart Hosp, Anyang, South Korea
[2] Natl Canc Ctr, Res Core Ctr, Biostat Collaborat Team, Goyang, South Korea
[3] Yonsei Univ, Dept Stat & Data Sci, Seoul, South Korea
[4] Pusan Natl Univ, Dept Obstet & Gynecol, Yangsan Hosp, Pusan, South Korea
[5] Natl Canc Ctr, Ctr Gynecol Canc, Goyang, South Korea
[6] Natl Canc Ctr, Ctr Clin Trials, Goyang, South Korea
[7] Natl Canc Ctr, Rare & Pediat Canc Branch, Goyang, South Korea
[8] Natl Canc Ctr, Immunooncol Branch, Div Rare & Refractory Canc, Res Inst, Goyang, South Korea
[9] Natl Canc Ctr, Grad Sch Canc Sci & Policy, Goyang, South Korea
[10] Imperial Coll London, Dept Gynecol Oncol, London, England
[11] Univ Calif Irvine, Irvine Med Ctr, Div Gynecol Oncol Obstet & Gynecol, Orange, CA 92668 USA
关键词
EPITHELIAL OVARIAN; SURGICAL CYTOREDUCTION; PERITONEAL CARCINOMATOSIS; INTRAPERITONEAL CHEMOHYPERTHERMIA; SELECTION CRITERIA; PROGNOSTIC-FACTORS; SURVIVAL; RESECTION; CHEMOTHERAPY; MANAGEMENT;
D O I
10.1200/JCO.21.02085
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
This study is to evaluate the survival impact of secondary cytoreductive surgery in patients with platinum-sensitive recurrent ovarian cancer. It contains 36 studies for meta-analysis and 57 studies for meta-regression and, to our knowledge, is the largest to date. In the meta-analysis, the complete cytoreductions were associated with better survival outcomes. In the linear regression model, the median overall survival time increased by 8.97% when the proportion of complete cytoreduction increased by 10%. Secondary cytoreductive surgery with maximal tumor resection increased significantly overall survival in platinum-sensitive recurrent ovarian cancer. PURPOSE The survival impact of secondary cytoreductive surgery in patients with platinum-sensitive recurrent ovarian cancer was studied. METHODS We identified published studies from 1983 to 2021 following our inclusion criteria from MEDLINE, EMBASE, and Cochrane library. To integrate the effect size of single-arm studies, meta-analysis was performed using death rate as a primary outcome. The effect of complete cytoreduction and optimal cytoreduction on survival was evaluated using meta-regression. The pooled death rate was presented with a 95% CI. The publication bias was evaluated with the funnel plot and Egger's test, and sensitivity analysis was performed. To overcome missing death rates, the linear regression model was performed on log-transformed median overall survival (OS) time using study size as a weight. RESULTS Thirty-six studies with 2,805 patients reporting death rates were used for this meta-analysis of the 80 eligible studies. There was strong heterogeneity, with the P value of the Cochrane Q test of < 0.0001 and Higgins's I-2 statistics of 86%; thus, we considered a random effect model. The pooled death rate was 44.2% (95% CI, 39.0 to 49.5), and both the complete and optimal cytoreductions were associated with better survival outcomes as significant moderators in the meta-regression model (P < .001 and P = .005, respectively). Although 14 studies were located outside the funnel plot, Egger's test indicated no publication bias (P = .327). A sensitivity analysis excluding 14 studies showed similar results. In the linear regression model on the basis of 57 studies, the median OS time increased by 8.97% and 7.04% when the complete and optimal cytoreduction proportion increased by 10%, respectively, after adjusting other variables. CONCLUSION Secondary cytoreductive surgery, resulting in maximal tumor resection, significantly prolongs OS in platinum-sensitive recurrent ovarian cancer.
引用
收藏
页码:1659 / +
页数:13
相关论文
共 80 条
[31]   Surgical cytoreduction in recurrent ovarian carcinoma in patients with complete response to paclitaxel-platinum [J].
Gronlund, B ;
Lundvall, L ;
Christensen, IJ ;
Knudsen, JB ;
Hogdall, C .
EJSO, 2005, 31 (01) :67-73
[32]   The role of secondary cytoreductive surgery for recurrent ovarian cancer [J].
Güngör, M ;
Ortaç, F ;
Arvas, M ;
Kösebay, D ;
Sönmezer, M ;
Köse, K .
GYNECOLOGIC ONCOLOGY, 2005, 97 (01) :74-79
[33]   Randomized Trial of Cytoreductive Surgery for Relapsed Ovarian Cancer [J].
Harter, P. ;
Sehouli, J. ;
Vergote, I ;
Ferron, G. ;
Reuss, A. ;
Meier, W. ;
Greggi, S. ;
Mosgard, B. J. ;
Selle, F. ;
Guyon, F. ;
Pomel, C. ;
Lecuru, F. ;
Zang, R. ;
Avail-Lundqvist, E. ;
Kim, J-W ;
Ponce, J. ;
Raspagliesi, F. ;
Kristensen, G. ;
Classe, J-M ;
Hillemanns, P. ;
Jensen, P. ;
Hasenburg, A. ;
Ghaem-Maghami, S. ;
Mirza, M. R. ;
Lund, B. ;
Reinthaller, A. ;
Santaballa, A. ;
Olaitan, A. ;
Hilpert, F. ;
du Bois, A. .
NEW ENGLAND JOURNAL OF MEDICINE, 2021, 385 (23) :2123-2131
[34]   Surgery for Recurrent Ovarian Cancer: Role of Peritoneal Carcinomatosis: Exploratory Analysis of the DESKTOP I Trial About Risk Factors, Surgical Implications, and Prognostic Value of Peritoneal Carcinomatosis [J].
Harter, P. ;
Hahmann, M. ;
Lueck, H. J. ;
Poelcher, M. ;
Wimberger, P. ;
Ortmann, O. ;
Canzler, U. ;
Richter, B. ;
Wagner, U. ;
Hasenburg, A. ;
Burges, A. ;
Loibl, S. ;
Meier, W. ;
Huober, J. ;
Fink, D. ;
Schroeder, W. ;
Muenstedt, K. ;
Schmalfeldt, B. ;
Emons, G. ;
du Bois, A. .
ANNALS OF SURGICAL ONCOLOGY, 2009, 16 (05) :1324-1330
[35]   Surgery in recurrent ovarian cancer:: The Arbeitsgemeinschaft Gynaekologische Onkologie (AGO) DESKTOP OVAR Trial [J].
Harter, Philipp ;
du Bois, Andreas ;
Hahmann, Maik ;
Hasenburg, Annette ;
Burges, Alexander ;
Loibl, Sibylle ;
Gropp, Martina ;
Huober, Jens ;
Fink, Daniel ;
Schroeder, Willibald ;
Muenstedt, Karsten ;
Schmalfeldt, Barbara ;
Emons, Guenter ;
Pfisterer, Jacobus ;
Wollschlaeger, Kerstin ;
Meerpohl, Hans-Gerd ;
Breitbach, Georg-Peter ;
Tanner, Berno ;
Sehouli, Jalid ;
AGO, O. C. .
ANNALS OF SURGICAL ONCOLOGY, 2006, 13 (12) :1702-1710
[36]  
JANICKE F, 1992, CANCER-AM CANCER SOC, V70, P2129, DOI 10.1002/1097-0142(19921015)70:8<2129::AID-CNCR2820700820>3.0.CO
[37]  
2-U
[38]   Cytoreductive surgery and HIPEC in peritoneal recurrent ovarian cancer: experience and lessons learned [J].
Koenigsrainer, Ingmar ;
Beckert, Stefan ;
Becker, Sven ;
Zieker, Derek ;
Fehm, Tanja ;
Grischke, Eva-Maria ;
Lauk, Olivia ;
Glatzle, Joerg ;
Bruecher, Bjoern ;
Wallwiener, Diethelm ;
Koenigsrainer, Alfred .
LANGENBECKS ARCHIVES OF SURGERY, 2011, 396 (07) :1077-1081
[39]   Platin-based chemotherapy and salvage surgery in recurrent ovarian cancer following negative second-look laparotomy [J].
Landoni, F ;
Pellegrino, A ;
Cormio, G ;
Milani, R ;
Maggioni, A ;
Mangioni, C .
ACTA OBSTETRICIA ET GYNECOLOGICA SCANDINAVICA, 1998, 77 (02) :233-237
[40]   Clinical trials and decision-making strategies for optimal treatment of relapsed ovarian cancer [J].
Ledermann, Jonathan A. ;
Raja, Fharat A. .
EUROPEAN JOURNAL OF CANCER, 2011, 47 :S104-S115